ClinicalTrials.Veeva

Menu

Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation (CICR-NAM_PK)

U

University Hospital Schleswig-Holstein (UKSH)

Status

Completed

Conditions

Respiratory Infection (for Example, Pneumonia, Bronchitis)
Community Acquired Pneumonia (CAP)
Inflammatory Bowel Disease (IBD)
COPD Acute Exacerbation
Respiratory Infection Virus

Treatments

Dietary Supplement: Controlled-ileocolonic-release nicotinamide (CICR-NAM): 500 mg/d
Dietary Supplement: Controlled-ileocolonic-release nicotinamide (CICR-NAM): 1000 mg/d

Study type

Interventional

Funder types

Other

Identifiers

NCT07156929
D 417/24

Details and patient eligibility

About

The diet of patients with reduced tryptophan serum levels that are either hospitalized for acute respiratory infection or treated for chronic inflammatory diseases such as inflammatory bowel diseases (in- or outpatients) is supplemented with controlled-ileocolonic-release nicotinamide (CICR-NAM) at doses of 500 mg or 1000 mg per day for four weeks. In the COVit-2 trial (NCT04751604), nicotinamide supplementation including CICR-NAM has been shown to accelerate physical recovery from mild-to-moderate COVID-19 (for publication, see References). The main objective of this open-label case series is to investigate the pharmacokinetics and metabolism of nicotinamide in patients with more severe respiratory infections or chronic inflammatory conditions. In addition, patients can optionally provide information on their quality of life and fatigue status.

Enrollment

28 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Serum tryptophan levels below normal range.
  • Acute, infectious respiratory disease requiring treatment (e.g. proven acute SARS-CoV-2 or influenza virus infection with inpatient treatment) or chronic inflammatory disease (e.g. chronic inflammatory bowel disease) in remission or in acute relapse (outpatient or inpatient treatment).

Exclusion criteria

  • Inability to give informed consent.
  • Pregnancy or breastfeeding.
  • Serious other illness, e.g. cancer.
  • Anemia: Hb <10 mg/dL.
  • Intake of medication to raise the pH value in the stomach (e.g. proton pump inhibitors, H2 receptor antagonists or antacids) in higher doses over a longer period of time.

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

28 participants in 2 patient groups

500 mg/d CICR-NAM
Active Comparator group
Description:
500 mg/d controlled-ileocolonic-release nicotinamide for 28 d
Treatment:
Dietary Supplement: Controlled-ileocolonic-release nicotinamide (CICR-NAM): 500 mg/d
1000 mg/d CICR-NAM
Active Comparator group
Description:
500 mg/d controlled-ileocolonic-release nicotinamide for 28 d
Treatment:
Dietary Supplement: Controlled-ileocolonic-release nicotinamide (CICR-NAM): 1000 mg/d

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems